The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Share News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.40
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.20 (6.061%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.40
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Fusion Antibodies shares drop after placing at 84% discount

Fri, 19th May 2023 11:43

Fusion Antibodies PLC - Belfast-based contract research organisation providing discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Raises GBP1.6 million through a placing and director subscription of 31.2 million shares at 5 pence per share, which is an 84% discount to the stock's close on Thursday of 32.06p. The placing is run by broker Allenby Capital Ltd. Fusion also launches a separate retail offer via the REX platform of up to 10.0 million shares at the same price, to raise up to an additional GBP500,000.

"We are pleased to say that we have been able to raise funds in an extremely challenging market, and this, combined with the cost saving measures that we will be implementing, will provide us with the necessary capital we need to progress the business," says Chief Executive Officer Adrian Kinkaid.

Current-stock price: 19.90 pence, down 37% in London on Friday

12-month change: down 65%

By Will Neill, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
30 Apr 2024 19:54

EARNINGS AND TRADING: Software Circle & Beximco report higher revenue

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
15 Apr 2024 13:29

Fusion Antibodies inks commercial contract for OptiPhage library

(Alliance News) - Fusion Antibodies PLC on Monday said that it has signed a commercial contract to develop an OptiPhage library for a non-human antibody species.

Read more
27 Feb 2024 14:18

TRADING UPDATES: Sondrel wins USD23 million contract

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 13:15

Fusion Antibodies gets first order under new services agreement

(Sharecast News) - Fusion Antibodies announced the receipt of its first purchase order under a master services agreement on Tuesday, which it agreed with a prominent diagnostics company on 14 February.

Read more
14 Feb 2024 12:52

Fusion Antibodies raises £1.38m as it seeks new customers

(Sharecast News) - Pre-clinical antibody specialist Fusion Antibodies announced a conditional fundraising of £1.38m before expenses on Wednesday, to help it target mo re industry conferences and customers and generate further supporting data.

Read more
14 Feb 2024 11:27

IN BRIEF: Fusion Antibodies raises GBP1.4 million via placing

Fusion Antibodies PLC - Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Conditionally raises GBP1.4 million before expenses via placing of 34.4 million shares at 4 pence each. The issue price represents a discount of 5.9% to Fusion's closing mid-market share price on Tuesday. Further, it intends to issue 1.5 million new shares to certain directors in lieu of or in satisfaction of salary and fees due to them and which shall be issued immediately following publication of its announcement. Also intends to grant a total of up to 3.8 million new share options to staff and senior management.

Read more
6 Feb 2024 11:48

Fusion Antibodies strikes follow-on research and development project

(Alliance News) - Fusion Antibodies PLC on Tuesday said it has won a follow-on project under a collaborative research and development agreement with an unnamed "US-based biotechnology company".

Read more
6 Feb 2024 10:05

AIM WINNERS & LOSERS: Beeks Financial Cloud is ahead of expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
1 Feb 2024 16:27

Fusion Antibodies confirms £0.28m tax credit

(Sharecast News) - Preclinical antibody discovery specialist Fusion Antibodies announced the successful receipt of a research and development tax credit from HMRC on Thursday.

Read more
1 Feb 2024 12:00

Fusion Antibodies gets tax credit from UK HMRC for OptiMAL platform

(Alliance News) - Fusion Antibodies PLC on Thursday announced the receipt of a research & development tax credit from UK HM Revenue & Customs for work performed on the development of its OptiMAL platform and other projects in bioinformatics.

Read more
4 Dec 2023 16:56

LONDON MARKET CLOSE: FTSE 100 slips as miners hold down index

(Alliance News) - Stock prices in London closed lower on Monday, with miners and oil firms holding down the FTSE 100 index.

Read more
4 Dec 2023 12:01

Fusion Antibodies revenue falls, losses widen in first half

(Sharecast News) - Contract research organisation Fusion Antibodies reported first-half revenue of £0.54m on Monday, down from £1.9m a year earlier.

Read more
4 Dec 2023 10:23

AIM WINNERS & LOSERS: Cornerstone FS to beat 2023 expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
4 Dec 2023 10:22

Fusion Antibodies shares fall with revenue despite "positive" outlook

(Alliance News) - Fusion Antibodies PLC on Monday reported a widened loss and reduced revenue for its latest half year, but said its growth prospects are "increasingly positive".

Read more
28 Nov 2023 12:09

Fusion Antibodies shares up on deal with US National Cancer Institute

(Alliance News) - Fusion Antibodies PLC on Tuesday said it has signed a collaboration agreement with the US National Cancer Institute to use its OptiMAL product to discover novel antibodies to treat certain targets.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.